SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 5,065.96 |
Enterprise Value ($M) | 4,981.57 |
Book Value ($M) | 316.01 |
Book Value / Share | 3.14 |
Price / Book | 16.03 |
NCAV ($M) | 245.98 |
NCAV / Share | 2.43 |
Price / NCAV | 20.59 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -2.33 |
Return on Assets (ROA) | -2.10 |
Return on Equity (ROE) | -2.77 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 2.89 |
Current Ratio | 2.89 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 440.50 |
Assets | 510.52 |
Liabilities | 194.52 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | 0.00 |
Net Income | 0.00 |
Earnings Per Share Basic And Diluted | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 0.00 |
Cash from Investing | 0.00 |
Cash from Financing | 0.00 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Janus Henderson Group Plc | 6.60 | 5.51 | |
13G/A | Vanguard Group Inc | 8.23 | 0.00 | |
13G/A | Point72 Asset Management, L.P. | 3.20 | -37.14 | |
13G/A | Suvretta Capital Management, Llc | 5.70 | 18.81 | |
13G/A | State Street Corp | 4.82 | -15.69 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
220,860 | 758,315 | 29.13 | |
265,725 | 1,042,016 | 25.50 | |
115,426 | 565,975 | 20.39 | |
52,349 | 468,291 | 11.18 | |
68,793 | 601,540 | 11.44 | |
(click for more detail) |
Similar Companies | |
---|---|
ANRO – Alto Neuroscience, Inc. | ANVS – Annovis Bio, Inc. |
BHC – Bausch Health Companies Inc. | BMY – Bristol-Myers Squibb Company |
CTLT – Catalent, Inc. |
Financial data and stock pages provided by
Fintel.io